Traditionally the pharmaceutical industry has followed one of two paths. They either look at a new molecule to develop an all-new solution or they copy. Innovate pharmaceuticals as their name suggests feel that there is a third and more inventive path.
This pathway looks at redeveloping long used medication to improve the way it works or change the field it works in.
By keeping the active unchanged and re-engineering the excipients Innovate pharmaceuticals have been able to reformulate and patent well recognized and safe pharmaceuticals. Changing their delivery route (e.g. tablet to liquid) or their side effect profile (e.g. reducing GI side effect) or even repurposing the drug to combat a disease area previously not identified for this particular medication (e.g. a pain medication now being used in cancer treatment)
Innovate pharmaceuticals have also pioneered a partnership program working with a wide range of other companies, academic institutions and charities in order to maximize the strengths of each partner to achieve the best results in shortened timelines. Innovate have found this approach to be synergistic and therefore results have been better than we would have been able to achieve working alone.
We believe that innovation encompasses more than just an internal process and should involve every aspect of our company our partners and most importantly the patients who will ultimately benefit from this new approach.
Innovate pharmaceuticals spent over six years developing a new formulation targeting the treatment of Glioma. They worked with a major excipient manufacturer to ensure the purity of the product that combines three ingredients. Each of these has been shown to have some activity against tumors and the company was looking for an easy to deliver, triple formulation that had more of an effect than each component on its own.
Liquid Trimarin is an oral product that is shelf stable for in excess of two years. A range of trials have been conducted by The Brian Tumor Centre of Excellence at Portsmouth University. Professor Geoff Pilkington’s team headed up by Dr. Richard Hill have looked at Liquid Trimarin’s effect on a range of brain cancers both adult and pediatric. The team studied each component and the combination against the current ‘gold standard’ Temozolomide.
The results from the trials for Liquid Trimarin have so far been exceptional. In all cases it was shown to be significantly better than the ‘gold standard” Temozolomide. In addition the combination’s effect was seen to be synergistic and significantly greater than the sum of the parts. In other words with Liquid Trimarin, one plus one plus one has been shown to equal five. It was therefore key to ensure that Liquid Trimarin was able to have this extrodinary effect without excessive toxicity. Trials were carried out on non-cancerous(normal) cells and Liquid Trimarin was shown to have very low toxicity. These early trials from one of the UKs’ premier brain tumor research centers are extremely exciting and may herald a real breakthrough in Glioma treatment.
The next step is to carry out further trials leading to full clinical trials. Innovate Pharmaceuticals are partnering with Imperial College London’s Brain Tumor research team and The Brian Tumor Centre of Excellence at Portsmouth University. To run an extensive series of in-vivo and mechanistic trialsto look into both how Liquid Trimarin kills brain tumor cells and how it works in life. Innovate Pharmaceuticals is very aware of how important Liquid Trimarin may prove in the fight to cure Glioma. To that end we are redoubling our effortsto accelerate the drive towards human clinical trials by working closely with a number of different partners in the field.